Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
251 Ballardvale St , Wilmington, MA, 01887, US
Why pharma needs automated AI security now.
By: Frank Balonis
Welcomes Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.
By: Charlie Sternberg
Dr. Abdul Mutlib is appointed the President of Frontage Laboratories, Canada, and will spearhead growth as he continues to serve as Chief Scientific & Strategy Officer.
By: Rachel Klemovitch
Strengthens BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701.
Forms a rare tumor business for Merck KGaA, Darmstadt, Germany, including SpringWorks’ portfolio and pimicotinib.
The U.S. launch of Conexxence and Bomyntra follows the FDA’s approval in March 2025.
Richard Thakor and Daniel Anderson will speak at the event in November.
Strengthens its global particle engineering capabilities.
Will manufacture SurVaxM, a novel immunotherapeutic vaccine designed to treat glioblastoma, for use in clinical trials.
Integrate Keystone’s Key-Pak child-resistant blister cards with Med-Con’s medication adherence prompting and monitoring application.
The company is investing $90 million to expand two U.S. facilities to enhance capacity and efficiency.
Villain offers extensive expertise in peptide and oligonucleotide development and manufacturing.
Collaboration aims to discover and develop novel therapeutics for cardiovascular disease using Novartis’ ProFoundry Platform.
It is the only ready-to-use liquid immunoglobulin therapy with (IgA) content and is set for commercialization in 2026.
The companies have released the first batch of Novalgen’s next-generation T-cell engager for first in-human clinical trials.
The collaboration now is progressing to the in vivo preclinical stage.
Will further expand its domestic capabilities to develop, produce and deliver medicines.
EVP & COO Todd Nelson reflects on Porton J-STAR's defining milestones, global network strategy, and what’s ahead as the company enters its third decade.
Released By Porton
The clinical site is expected to be completed and ready for media fill by the end of 2029.
The company’s label updates are for its CAR T cell therapies, Breyanzi and Abecma.
Is purpose-built for manufacturing high-quality plasmid DNA and viral vectors.
Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions.
Hervé Hoppenot will retire after 11 years of leading the company through major expansion.
Will commence cell therapy process development and clinical manufacturing services at AGC Inc.’s Yokohama Technical Center.
Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments.
Will develop and commercialize a potential treatment for obesity and metabolic disease based on technology licensed from the U.S. Department of Veterans Affairs.
Addressing increasing complexity, cost of drug development, and navigating regulatory compliance.
By: Kristin Brooks
Will add further sterile fill/finish capacity over the course of the next year.
Agnus joins Bora Group from KBI Biopharma, where he led global business development.
ST16 Semi-Automated Aggregation Station combines software and flexible hardware to help optimize productivity, improve operational efficiency and streamline processes.
J.D. Mowery brings nearly 25 years of experience in the CDMO and biopharmaceutical industries.
Will combine their biomanufacturing facilities to create a global service for biologics development and supply.
The newly acquired facility provides drug product manufacturing services for sterile injectables.
This strategic partnership provides end-to-end visibility and best-in-class track and trace for Praxis’s customer base.
This integrated solution follows the company’s acquisition of Pharmacontrol Electronic and combines technologies.
This acquisition enhances Systech’s product offerings and enables it to offer a more comprehensive product portfolio to its customers.
Offers quick compliance, avoids delays, and optimizes production with multi-scan and mobile flexibility.
ATP-bioluminescence and regulatory advancements address unmet manufacturing and testing needs.
By: Brice Chasey
Synnott has extensive experience in global CRO operations and management and brings more than 20 years of experience in biomedical research.
Novartis cuts approximately 430 employees from East Hanover HQ, and 34 employees in San Diego.
Will conduct an immunohistochemistry study to accelerate HT-KIT.
CGMP cytokines now available for Charles River’s Cell Therapy Flex Platform.
Offers biotechnology developers access to scientific expertise and an ecosystem of discovery, development and manufacturing services.
Alliance aims to advance ADC development and manufacturing services.
Provides early insights into how therapeutics interact with non-human protein targets in vitro.
Charles River will serve as the CDMO to produce the drug products for FibroBiologics’ upcoming clinical trial.
Quotient Sciences' chief executive talks about how the CDMO is positioning itself to stay ahead of the curve.
By: Tim Wright
Exploring how CDMO specialization is addressing scalability and making advanced cell-based therapies possible.
Terumo BCT and Charles River partner on cell therapy innovation.
Charles River will help advance the FRF’s gene therapy through clinical trials.
Will develop the plasmid DNA for AAVantgarde’s Stargardt’s disease program (AAVB-039), using its AAV-intein platform.
The Gates Institute will leverage Charles River’s cell and gene therapy CDMO expertise to develop lentiviral vectors for use in CAR T-cell therapies.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
